Addyi is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because it:

Addyi (flibanserin)is used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It is subject to aRisk Evaluation and Mitigation Strategy (REMS) programbecause of its potential to causesevere hypotension (low blood pressure) and syncope (fainting), especially when taken with alcoholor moderate-to-strong CYP3A4 inhibitors.

The REMS program requires healthcare providers and pharmacists to be certified before prescribing or dispensing Addyi. Patients must be counseled on the risks, and alcohol use is strictly contraindicated while taking this medication.

B. is an emergency oral contraceptive→ Incorrect. Addyi is not a contraceptive; it treats HSDD.

C. contains an opioid analgesic→ Incorrect. Addyi is not an opioid; it affects serotonin and dopamine receptors.

D. is a monoclonal antibody→ Incorrect. Addyi is a non-hormonal serotonin receptor agonist/antagonist, not a monoclonal antibody.

Incorrect Answer Choices:Pharmacy Technician References:

PTCB PTCE Exam Content Outline (Medication Safety and REMS Programs)

FDA REMS Database for Addyi (Flibanserin)

Lexicomp Drug Monograph on Addyi

Mosby’s Pharmacy Technician Exam Review